Early relapse after rituximab treatment in a patient with seronegative neuromyelitis optica spectrum disorder: a case report
Rituximab (RTX) is a monoclonal antibody that targets CD20 on B cells and is used to reduce the relapse risk in neuromyelitis optica spectrum disorder (NMOSD). Some patients experience relapse or exacerbation shortly after RTX treatment. We report a 54-year-old female with seronegative NMOSD who relapsed soon after RTX treatment.
Authors
- Yoon‐Ho Hong (ORCID: https://orcid.org/0000-0002-3325-6358)
- Ju‐Hee Lee (ORCID: https://orcid.org/0000-0003-4147-9794)
Institutions
- Kangwon National University Hospital (KR)
Publication Details
- Journal
- Annals of Clinical Neurophysiology
- Published
- 2024-09-26
- DOI
- https://doi.org/10.14253/acn.24001
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00